Tau Ventures is an AI-first, seed-first VC fund in the heart of Silicon Valley. We are currently $85M+ AUM, focus on digital health and enterprise, with a little bit of automation (cars, robots, logistics), and writing initial checks typically of $500K. More at https://www.linkedin.com/pulse/announcing-tau-fund-ii-our-newest-tauventures, https://www.linkedin.com/pulse/announcing-tau-opportunity-fund-our-newest-tauventures, and https://www.linkedin.com/pulse/announcing-tau-ventures-amit-garg.Our 60+ investments include Oak Street Health (https://www.oakstreethealth.com, primary care, sold for $10.6B) AbSci (http://absci.com, drug discovery, IPO $2.1B) ArmorCode (http://armorcode.com, application security), Biotia (http://biotia.io, analyze pathogen genomes to prevent hospital contamination), Cerby (http://cerby.com, cybersecurity to harness shadow IT), Elemental Machines (http://elementalmachines.io, IoT to improve production of foods+drugs), FidoCure (https://fidocure.com, treat cancer in dogs), Infinitus (http://infinitus.ai, helping patients navigate healthcare), Iterative Health (http://iterativehealth.com, computer vision for colon cancer), RapidDeploy (http://rapiddeploy.com, unified public safety), RubiconMD (http://rubiconmd.com, referral service for primary care physicians), Signos (http://signos.com, weight loss through glucose monitoring), Totient (http://totient.bio, cancer drug discovery), among others.

Principal at Samsung NEXT Ventures, note Samsung has two other main investment arms. We are headquartered in the heart of Silicon Valley, with offices in New York, Korea and Israel, including my sister teams focused on acquisitions and accelerators. I focus on software especially Internet / consumer technologies, investing $250K to $3M in seed, series A or B, and helping them partner with Samsung to grow and make a meaningful difference in people's lives.Key investments I have worked on include UniKey (http://unikey.com, smart locks), nuTonomy (http://nutonomy.com, self-driving cars, sold for $450M), BioBeats (http://biobeats.com, machine learning for human well-being, acquired by Huma / Medapod), Glooko (http://glooko.com, diabetes management platform), Cohero Health (http://coherohealth.com, respiratory management), Terapede (http://terapede.com, low-dosage X-ray detection), Figure1 (http://figure1.com, medical communication), HealthifyMe (http://healthifyme.com, fitness and health-tracking), Healthy.io (http://healthy.io, home-based urinalysis), and RapidDeploy (http://rapiddeploy.com, cloud-based emergency response).

The core idea is to develop a FICO score for health. As of May 2019 the company is a series D that has raised $137M and valued at $450M. Investors include Charles River, Menlo, First Round, Greylock, Rock Health, WTI, Felicis, Ribbit, Foundation, Andreessen Horowitz, Aquiline Technology Growth, Greenspring, Hanwha.

Senior Associate investing out of Norwest's fund XI of $1.2B, focused on Internet / consumer businesses. Norwest has funded more than 600 companies since its inception in 1961 and has $13B AUM.

As a product manager I led Google Images and various internationalization efforts, including bringing Picasa (Photos) to 139 countries and being part of the 6-person team that acquired a company that seeded Google Brazil and LatAm engineering headquarters. As a business analyst I focused on AdWords and guiding those business managers into making better decisions.